Pharmacogenomics Market Hits $3,180.5 million in 2025 with 8.8% CAGR

Pharmacogenomics market valued at $3,180.5 million in 2025 and is projected to reach $7,344.7 million by 2035, growing at a CAGR of 8.8% during the forecast period (2026-2035). The market encompasses products, services, and technologies that analyze genetic variations to optimize drug efficacy, minimize adverse drug reactions, and enable precision medicine approaches across therapeutic areas.

Browse the full report description of “Pharmacogenomics Market Size, Share & Trends Analysis Report by Product & Service (Instruments, Consumables & Reagents, Software, and Services) by Technology (PCR, Microarray, NGS, Mass Spectrometry, and Others) by Application (Oncology, Cardiology, Neurology, Infectious Diseases, Psychiatry, Pain Management, and Others) by End User (Hospitals & Clinics, Diagnostic Labs, Pharma & Biotech Companies, Research Institutes, and CROs) Forecast Period, (2026-2035)” at https://www.omrglobal.com/industry-reports/pharmacogenomics-market

The market growth is further supported by expanding applications across oncology, cardiology, neurology, infectious diseases, psychiatry, and pain management, driven by the increasing prevalence of chronic and complex diseases. End users including hospitals & clinics, diagnostic labs, pharmaceutical & biotechnology companies, research institutes, and contract research organizations (CROs) are adopting pharmacogenomic solutions to enhance patient outcomes and streamline drug development.

Global databases and initiatives such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) and PharmGKB provide comprehensive genetic and clinical data that strengthen evidence-based adoption of pharmacogenomic testing, informing dosing guidelines and therapeutic strategies globally.

Key Statistics: Pharmacogenomics at a Glance

• More than 350 million patients globally are estimated to benefit from pharmacogenomic-guided therapy by 2030, particularly in oncology, cardiology, and neurology.
• Over 70% of new molecular entities under clinical development now consider pharmacogenomic profiling to optimize safety and efficacy.
• Hospitals and diagnostic laboratories together account for more than 60% of current pharmacogenomic testing demand globally.

Key Innovators Driving Pharmacogenomics Transformation

The key players in the pharmacogenomics market include Danaher Corporation, F. Hoffmann-La Roche Ltd, Illumina, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc, among others.

• In June 2025, Thermo Fisher Scientific expanded its pharmacogenomics portfolio with the launch of an enhanced NGS-based testing panel designed to support multi-gene drug response analysis across oncology and cardiology applications.
• In April 2025, Illumina, Inc. announced advancements in its clinical sequencing solutions aimed at improving scalability and affordability for pharmacogenomic testing in hospital and reference laboratory settings.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Product & Service
  • By Technology
  • By Application
  • By End User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Danaher Corporation, F. Hoffmann-La Roche Ltd, Illumina, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Pharmacogenomics Market Report Segment

By Product & Service

• Instruments
• Consumables & Reagents
• Software
• Services

By Technology

• PCR
• Microarray
• NGS
• Mass Spectrometry
• Others

By Application

• Oncology
• Cardiology
• Neurology
• Infectious Diseases
• Psychiatry
• Pain Management
• Others

By End User

• Hospitals & Clinics
• Diagnostic Labs
• Pharma & Biotech Companies
• Research Institutes
• CROs

Global Pharmacogenomics Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/pharmacogenomics-market